Sodium-L-arginine succinate – a new vasodilating medicine for the treatment and prophylaxis of doxorubicin-induced cardiotoxicity

Authors

  • Vadim V. Valeev I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St.Petersburg, Russia
  • Alexander P. Trashkov I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St.Petersburg, Russia
  • Alexey L. Kovaleko Toxicology Institute of the Federal Medical and Biological Agency, St.Petersburg, Russia
  • Andrey Yu. Petrov I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St.Petersburg, Russia
  • Andrey G. Vasiliev I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St.Petersburg, Russia

Keywords:

arginine; Doxorubicin; succine acid; antracyclic cardiomyopathy; peroxidation.

Abstract

The purpose: to ascertain possible cardioprotective effect of Sodium-L-arginine Succinate in case of myocardial lesions caused by Doxorubicin in rats. Methods. The effectiveness of the drug was assessed by morphometric and biochemical changes reflecting peroxidation intensity and structural and functional changes in myocardium. Results. Sodium-L-arginine Succinate used for the treatment and prophylaxis of antracyclic cardiomyopathy was demonstrated to decrease Doxorubicin effects lessening cardiomyocytal destruction and the left ventricular dysfunction with myocardial hypertrophy.

Downloads

Published

2016-11-21

Issue

Vol. 60 No. 4 (2016)

Section

Original research

How to Cite

[1]
2016. Sodium-L-arginine succinate – a new vasodilating medicine for the treatment and prophylaxis of doxorubicin-induced cardiotoxicity. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 60, 4 (Nov. 2016), 52–57.